News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB), Bayer AG (BAY.F) Drugs Fail to Slow MS Progression


7/18/2012 7:06:38 AM

The most commonly prescribed multiple sclerosis drugs, including those made by Biogen Idec Inc. (BIIB) (BIIB), Bayer AG (BAYN) and Merck KGaA, failed to slow disability progression in a long-term study that raises new questions on whether the treatments can achieve that goal. Researchers compared historical outcomes for MS patients in British Columbia to assess the use of interferon beta drugs. The results, published online in the Journal of the American Medical Association, found the medicines didn’t delay progress of the patients’ disability.

Read at BusinessWeek
Read at Red Orbit
Read at New York Times
Read at CBC
Read at Medical News Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES